Chargement en cours...
Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients
BACKGROUND: The main pathophysiological basis of coronavirus disease 2019 (COVID-19) causing respiratory failure is a cytokine storm and interleukin-6 (IL-6) is an important component of the COVID-19 cytokine storm. As a specific antagonist of IL-6, tocilizumab may block the cytokine storm of COVID-...
Enregistré dans:
| Publié dans: | World J Clin Cases |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Baishideng Publishing Group Inc
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7479568/ https://ncbi.nlm.nih.gov/pubmed/32953852 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v8.i17.3763 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|